These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15539385)

  • 1. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
    Naka T; Boltze C; Kuester D; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Am J Clin Pathol; 2004 Dec; 122(6):926-30. PubMed ID: 15539385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
    Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
    Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
    Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
    Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions.
    Naka T; Boltze C; Kuester D; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Roessner A
    Am J Clin Pathol; 2005 Aug; 124(2):288-94. PubMed ID: 16040302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
    Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
    Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
    Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
    Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
    Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability.
    Naka T; Boltze C; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
    Cancer; 2003 Nov; 98(9):1934-41. PubMed ID: 14584077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
    Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
    Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
    Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F
    Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
    Häckel CG; Krueger S; Grote HJ; Oshiro Y; Hodges S; Johnston DA; Johnson ME; Roessner A; Ayala AG; Czerniak B
    Cancer; 2000 Sep; 89(5):995-1003. PubMed ID: 10964329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
    Hsu CP; Shen GH; Ko JL
    Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
    Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Yang SF; Hsieh YS; Lin CL; Hsu NY; Chiou HL; Chou FP; Chu SC
    Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
    Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
    Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.